Project Grant R44HG010603

Award Date 9/17/19
Completion Date 8/31/23
Dollars Obligated $5.1M
Federal Grant Program
93.172
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) provides $383,482 to Electronic Biosciences, Inc. to develop the SPINSEQ platform, an innovative RNA sequencing technology. The goal is to create a highly precise and accurate solution for transcriptomic and epitranscriptomic analysis that can overcome the limitations of existing RNA sequencing methods. Key focus areas include maintaining RNA integrity, ensuring accurate sequencing,...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $302,605.00 to Chimerna Therapeutics, Inc. to develop a scalable and low-cost method for semi-synthesis of site-specifically labeled circular RNAs (circRNAs). The goal is to improve the endosomal escape of RNA therapeutics by conjugating circRNAs with lipids to facilitate their delivery and therapeutic effect. The project aims...
This Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), is funding the development of novel signal amplification technologies by Molecular Instruments, Inc. to enable automated, ultrasensitive, and multiplex imaging of RNA and protein expression in biological samples. The $1,099,625 award supports the engineering of two key capabilities: 1) a chromogenic signal amplification...
This $256,000 National Science Foundation Engineering grant supports the development of an easy RNA adenylation method for deep sequencing of picogram RNA samples with high resolution. Specifically, Ezrabio Inc. will develop a versatile and cost-effective library construction technology that enables protein translation monitoring on a variety of biological samples. The proposed technology relies on a novel enzyme system capable of 5' adenylation and 3' polyadenylation of RNA fragments to...
The National Institute of General Medical Sciences (NIGMS) awarded a $700,000 Project Grant under the Biomedical Research and Research Training (CFDA 93.859) program to Mirimus, Inc., a self-certified small disadvantaged business located in Brooklyn, NY. The grant funding, with a period of performance from September 20, 2024 to April 19, 2025, will support the creation of next-generation RNA interference (RNAi) therapeutics and the development of an in vivo mouse model to evaluate their efficacy...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research federal grant program (CFDA 93.172), will provide $215,088 to Directseq Biosciences, Inc. to develop an exhaustive de novo RNA sequencing method using next-generation mass spectrometry (NGMS-seq). The objective is to create a technology that can directly identify and sequence every RNA species in a sample, while also comprehensively profiling all RNA modifications, without bias....
This Project Grant award, totaling $432,834, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training federal grant program (CFDA 93.859). The award supports the development of an "enzyme-free, label-free quantitative microarray technology" to enable highly sensitive and quantitative measurement of small nucleic acid targets, such as microRNAs, with applications in liquid biopsy diagnostics. The research strategy...
This Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $440,287 to GE Medical Systems Information Technologies, Inc. to establish a simplified and accessible procedure for multi-analyte simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This approach aims to democratize biobanking for low-resource institutes by enabling molecular analysis from smaller tumor samples, including those less than 10,000...
The National Institute of General Medical Sciences (NIGMS) awarded a $307,257 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Sxrna Technologies, Inc. to develop a rapid cloning technology called SXRNA-SELECT. This technology aims to decrease the time required to clone mammalian cells and increase protein yields for biotherapeutic production. The key objectives are to optimize the delivery protocol for plasmids and SXRNA-bait, demonstrate selection...
This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I project under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) aims to develop a next-generation sequencing platform for discovering small molecules that target RNA. The $303,445 award to Endura Therapeutics Inc. in San Diego, CA will establish an assay to detect RNA-drug interactions and identify RNA structures amenable to small molecule binding. The goal is to address...

DEVELOPMENT OF CHIMERIC READ AMPLIFICATION INTO A ROBUST METHOD FOR PROFILING TARGETS OF SPECIFIC MICRORNAS AND GLOBAL AMPLIFICATION OF ALL MICRORNA:MRNA PAIRINGS TRANSCRIPTOME-WIDE - PROJECT SUMMARY POST-TRANSCRIPTIONAL REGULATION BY MICRORNAS IS FUNDAMENTAL FOR CELLULAR HOMEOSTASIS. MICRORNAS ARE SMALL NON-CODING RNAS THAT FINE TUNE GENE EXPRESSION BY BASE PAIRING TO COMPLEMENTARY SEQUENCES IN TARGET MESSENGER RNA (MRNA) MOLECULES. A SINGLE MICRORNA CAN HAVE MULTIPLE TARGETS ALLOWING FOR COORDINATED REGULATION OF MRNA NETWORKS. THE IMPORTANCE OF MICRORNA REGULATION IS EVIDENCED NOT ONLY BY THEIR EVOLUTIONARY CONSERVATION BUT ALSO BY THE INVOLVEMENT OF MICRORNAS IN NEARLY EVERY BIOLOGICAL PROCESS INCLUDING PROLIFERATION, INFLAMMATION, DEVELOPMENT, AND METABOLISM. MISREGULATION OF INDIVIDUAL MICRORNAS OR GLOBAL MICRORNA PROCESSING HAS IMPORTANT CONSEQUENCES FOR DEVELOPMENT, PHYSIOLOGY, AND DISEASE. ABERRANT MICRORNA EXPRESSION HAS BEEN LINKED TO MANY DISEASES RANGING FROM CANCER TO CARDIAC FAILURE, AND MICRORNAS HAVE BECOME ATTRACTIVE TARGETS AND TOOLS FOR THERAPEUTIC APPROACHES. PRECISE TARGET IDENTIFICATION OF MICRORNAS IS ESSENTIAL TO UNDERSTAND THEIR FUNCTIONAL ROLE. CURRENT METHODS TO IDENTIFY MICRORNA TARGETS ARE LIMITED, AS THEY HAVE HIGH FALSE-POSITIVE RATES, ARE UNABLE TO DEFINITIVELY DISTINGUISH DIRECT FROM INDIRECT MICRORNA-TARGET INTERACTIONS OR ARE UNABLE TO PROFILE LOW-ABUNDANCE MICRORNAS. TO THIS END WE HAVE APPLIED OUR PREVIOUSLY DEVELOPED ENHANCED CROSSLINKING AND IMMUNOPRECIPITATION (ECLIP) TECHNOLOGY TO DEVELOP A SPECIALIZED ALTERNATIVE, CHIMERIC-ECLIP, TO UNAMBIGUOUSLY IDENTIFY MICRORNA TARGETS IN A TRANSCRIPTOME-WIDE MANNER. CHIMERIC-ECLIP IS BASED ON AGO2 ECLIP AND INCLUDES A LIGATION STEP WHERE MICRORNA AND MRNA FRAGMENTS ARE LIGATED TO EACH OTHER FORMING CHIMERIC RNA MOLECULES THAT CAN THEN BE SEQUENCED. DIRECT TARGETS OF INDIVIDUAL MICRORNAS ARE EASILY IDENTIFIABLE FROM CHIMERIC-ECLIP DATA USING MICRORNA:MRNA CHIMERIC READS. THE WORK PROPOSED HERE WILL EXPAND THE PREVIOUSLY DEVELOPED CHIMERIC-ECLIP TECHNOLOGY TO INCLUDE MICRORNA- AND GENE-SPECIFIC READ ENRICHMENT METHODS, AND A USER-FRIENDLY ANALYSIS PACKAGE RESULTING IN A ROBUST AND VERSATILE CHIMERIC-ECLIP KIT FOR WIDE-SPREAD USE BY ACADEMIC AND BIOTECHNOLOGY INDUSTRIES, AS OUTLINED IN THE FOLLOWING AIMS: 1. EXPAND DIRECT PROFILING OF MICRORNA TARGETS WITH PROBE-BASED CHIMERIC-ECLIP 2. REFINE SOFTWARE TOOLS FOR ANALYSIS OF CHIMERIC-ECLIP DATA TO STRENGTHEN KEY CUSTOMER-FACING FEATURES 3. CONDUCT EXPANDED BETA TESTING AND FINALIZE COMMERCIALIZATION OF THE ALL-INCLUSIVE CHIMERIC-ECLIP KIT ECLIPSE BIO IS AN IDEAL CANDIDATE TO PERFORM THE AIMS DESCRIBED ABOVE DUE TO OUR EXPERTISE IN GENOMICS, RNA PROCESSING, AND COMPUTATIONAL BIOLOGY. THE ABOVE AIMS WILL ENABLE ROBUST MICRORNA TARGET MAPPING TO BE PERFORMED USING A STANDARD METHOD BY ALL BIOMEDICAL RESEARCHERS AND WILL ALLOW FOR RIGOROUS VALIDATION OF MICRORNA SPECIFICITY. THE ABILITY TO PROPERLY ASSESS THERAPEUTIC MICRORNA-LIKE MOLECULES WILL PROVIDE SIGNIFICANT BENEFIT TO RESEARCHERS STUDYING MICRORNA REGULATION AND COMPANIES DEVELOPING RNA THERAPIES.

Posted 9/22/21, 12:00 AM